RemeGen has submitted a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for IgAN, which if approved would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback